News - martin.laver@ukkidney.org

Hand writing about Avacopan Update
September 2nd, 2026
The MHRA Suspends Avacopan for New Patients
Following review, the MHRA has concluded that the available evidence no longer supports a positive benefit-risk balance for Avacopan Vifor (previously known as Tavneos), used in combination with rituximab or cyclophosphamide for adults with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).
Read More